Geneva, March 20 -- International Clinical Trials Registry received information related to the study (KCT0011665) titled 'An Observational Study to Evaluate Quality of Life, Safety, and Efficacy of Bispecific Antibody Administration in Combination with Tocilizumab in Patients with Multiple Myeloma' on Feb. 27.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Non-RCT
Primary Sponsor: The Catholic University of Korea, Seoul St. Mary's Hospital
Condition:
Neoplasms
Intervention:
Drug : Tocilizumab: Administer 8 mg/kg intravenously or subcutaneously over 1 hour (maximum dose of 800 mg). May be repeated after a minimum of 8 hours, up to...